Telapristone Acetate
Sponsors
Repros Therapeutics Inc., Northwestern University
Conditions
BRCA1 Mutation CarrierBRCA2 Mutation CarrierDuctal Breast Carcinoma In SituEndometriosisLobular Breast Carcinoma In SituStage 0 Breast CancerStage IA Breast CancerStage IB Breast Cancer
Phase 2
Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis
CompletedNCT01728454
Start: 2013-05-02End: 2017-03-15Updated: 2019-07-23
Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer
NCT01800422
Start: 2013-06-30End: 2022-03-31Target: 50Updated: 2020-01-18
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
CompletedNCT02301897
Start: 2015-03-16End: 2017-06-02Updated: 2019-06-19
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
CompletedNCT02314156
Start: 2015-10-31End: 2021-05-31Updated: 2023-02-22
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
CompletedNCT02323646
Start: 2015-02-12End: 2017-04-06Updated: 2019-06-25
An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
TerminatedNCT02811159
Start: 2016-07-26End: 2017-05-04Updated: 2019-06-27